{"entity":{"id":"nct07240766","kind":"trial","name":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","aka":[],"tldr":"A phase 2 trial of nimotuzumab in pancreatic cancer, run by Zhejiang University, now recruiting.","summary":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation is a phase 2, interventional study registered as NCT07240766 by Zhejiang University, with a registry enrolment figure of 40 participants, started 2026-02-15 and due to reach its primary completion in 2027-05-15. Interventions recorded: HRS-4642+AG+Nimotuzumab. Conditions listed: Borderline Resectable Pancreatic Adenocarcinoma. Primary outcome: 12-month Event-Free Survival (EFS) rate. Pancreatic eligibility wording from the registry: \"* Histopathologically confirmed pancreatic cancer (originating from the pancreatic ductal epithelium)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07240766","url":"https://clinicaltrials.gov/study/NCT07240766"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["nimotuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07240766","phase":"2","setting":"Phase II Study of HRS-4642 in Combination With Nimotuzumab and Chemotherapy for Subjects With Borderline Resectable Pancreatic Cancer With KRAS G12D Mutation","sponsor":"Zhejiang University","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07240766/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"drug":[{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}